Dapagliflozin Mitigates Cardiotoxic Effects of Sunitinib via the AMPKα-PPARα Pathway and Increases Renal Cell Carcinoma Sensitivity to Sunitinib - Top-Institutions - MDSpire

Dapagliflozin Mitigates Cardiotoxic Effects of Sunitinib via the AMPKα-PPARα Pathway and Increases Renal Cell Carcinoma Sensitivity to Sunitinib

  • By

  • Shi-yu Huang

  • Min Hu

  • Yu-jie Chen

  • Jia-chen Liu

  • Zhi-yuan Yao

  • Zhi-yuan Chen

  • Xiu-heng Liu

  • Lei Wang

  • December 15, 2025

  • 0 min

Share

Top Institutions in Urology

Brief introduction explaining scope and methodology.

  • #1

    MD Anderson Cancer Center
    MD Anderson Cancer Center

    Houston, TX

    Key Differentiators

    • Oncology
    • Cardio-Oncology
    • Renal Cell Carcinoma

  • #2

    Dana-Farber Cancer Institute
    Dana-Farber Cancer Institute

    Boston, MA

    Key Differentiators

    • Oncology
    • Cardio-Oncology
    • Molecular Pharmacology

  • #3

    Cleveland Clinic
    Cleveland Clinic

    Cleveland, OH

    Key Differentiators

    • Cardiology
    • Cardio-Oncology
    • Nephrology

  • #4

    Memorial Sloan Kettering Cancer Center
    Memorial Sloan Kettering Cancer Center

    New York, NY

    Key Differentiators

    • Oncology
    • Cardio-Oncology
    • Pharmacology

Original Source(s)

Dapagliflozin Mitigates Cardiotoxic Effects of Sunitinib via the AMPKα-PPARα Pathway and Increases Renal Cell Carcinoma Sensitivity to Sunitinib

  • by Shi-yu Huang, Min Hu, Yu-jie Chen, Jia-chen Liu, Zhi-yuan Yao, Zhi-yuan Chen, Xiu-heng Liu, Lei Wang

  • December 15, 2025

Related Content

Editorial: Cardiovascular risks in cardiovascular-kidney-metabolic syndrome: mechanisms and therapies

A Narrative Review of Atrial Fibrillation in the Perioperative Period Following Non-Cardiac Surgery

The effect of sodium restricted diet on the prognosis of heart failure patients: a systemic review and meta-analysis